Product image of Nuvaring (Ethinylestradiol, Etonogestrel) supplied by GNH India

Nuvaring

Active Ingredient:
Ethinylestradiol, Etonogestrel
Origin:
EU

Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Nuvaring, is a combined hormonal contraceptive presented as a vaginal ring that releases 0.015 mg/day ethinylestradiol and 0.12 mg/day etonogestrel for vaginal use. It prevents pregnancy in women of reproductive age by suppressing ovulation and modifying cervical mucus and the endometrial lining.

GNH India supplies Nuvaring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this contraceptive device across global markets.

Manufacturer / TM Owner

Organonhealthcare Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Nuvaring, a combined hormonal contraceptive, is indicated for prevention of pregnancy.
  • Contraception: Prevents pregnancy by inhibiting ovulation and altering cervical mucus and endometrial lining.
  • Family planning: Offers a reversible, user‑controlled method of birth control for women seeking long‑term protection.
  • Birth control: Reduces the risk of unintended pregnancy during regular sexual activity.

How It Works

  • The ring continuously releases low doses of ethinylestradiol, an estrogen, and etonogestrel, a progestogen. Ethinylestradiol suppresses the mid‑cycle surge of luteinizing hormone, while etonogestrel inhibits follicle‑stimulating hormone release, together preventing the development of a dominant follicle and ovulation. The progestogen also thickens cervical mucus and induces endometrial changes that impede sperm penetration and implantation.

Side Effects

Nuvaring may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea
  • Headache
  • Vaginal irritation or discharge
  • Breast tenderness
  • Spotting between periods

Serious or Rare Side Effects

  • Deep vein thrombosis or pulmonary embolism
  • Severe allergic reaction (anaphylaxis)
  • Hepatic dysfunction or jaundice

Precautions & Warnings

  • Before prescribing Nuvaring, clinicians should evaluate several safety considerations.
  • Medical history: Assess for personal or family history of thromboembolic disorders.
  • Smoking status: Avoid use in women over 35 who smoke.
  • Medication review: Identify concomitant drugs that may reduce contraceptive efficacy.
  • Pregnancy status: Contraindicated in pregnancy; confirm negative test before initiation.
  • Breastfeeding: Not recommended during lactation.
  • Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Nuvaring can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid)

  • Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin) – may markedly reduce hormone levels.
  • Certain antiretrovirals (e.g., efavirenz) – can decrease contraceptive efficacy.
  • Strong antifungal agents (e.g., ketoconazole) – may increase hormone concentrations and risk of side effects.

Moderate Interactions (Monitor Closely)

  • Rifampin and other potent antibiotics – may lower effectiveness of the ring.
  • Herbal supplements such as St. John’s wort – can accelerate hormone metabolism.

Frequently Asked Questions

Nuvaring is a combined hormonal contraceptive delivered via a vaginal ring and is indicated for the prevention of pregnancy in women of reproductive age. It provides a reversible, user‑controlled method of birth control that does not require daily dosing.

Ethinylestradiol suppresses the luteinizing hormone surge, while etonogestrel inhibits follicle‑stimulating hormone release. Together they prevent ovulation, thicken cervical mucus, and modify the endometrial lining, creating an environment that blocks sperm penetration and implantation.

The prescriber determines the regimen. Nuvaring is designed to release approximately 0.015 mg of ethinylestradiol and 0.12 mg of etonogestrel per day over a three‑week period, after which the ring is removed for a one‑week ring‑free interval.

Nuvaring is contraindicated in pregnancy (pregnancy category X) and should not be used by women who are pregnant. It is also not recommended during breastfeeding because hormonal exposure may affect milk production and infant safety.

Enquiries are submitted via the product page at gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both deliver ethinylestradiol and a progestogen, but Nuvaring provides continuous low‑dose hormone release through a vaginal ring, eliminating the need for daily oral dosing. This can improve adherence and reduce gastrointestinal side effects, while maintaining comparable contraceptive efficacy.

Store Nuvaring at room temperature, preferably below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and extreme heat to maintain the integrity of the hormone release system.

The ring is inserted into the vagina by the user and left in place for three weeks. After three weeks it is removed for a one‑week interval, during which a withdrawal bleed typically occurs, after which a new ring is inserted.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and severe allergic reactions (anaphylaxis). Women should be monitored for signs of blood clots, chest pain, shortness of breath, or any sudden allergic symptoms.

Nuvaring should not be used by women with a history of blood‑clotting disorders, current pregnancy, or those who are breastfeeding. It is also contraindicated for smokers over age 35, women with certain liver diseases, or those taking medications that markedly reduce its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Etonogestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT